pHLIP peptide targets nanogold particles to tumors by Yao, Lan et al.
University of Rhode Island
DigitalCommons@URI
Physics Faculty Publications Physics
2013
pHLIP peptide targets nanogold particles to
tumors
Lan Yao
University of Rhode Island
Jennifer Daniels
University of Rhode Island
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/phys_facpubs
Terms of Use
All rights reserved under copyright.
This Article is brought to you for free and open access by the Physics at DigitalCommons@URI. It has been accepted for inclusion in Physics Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Yao, L., Daniels, J., Moshnikova, A., Kuznetsov, S., Ahmed, A., Engelman, D. M., Reshetnyak, Y. K., & Andreev, O. A. (2013). pHLIP
peptide targets nanogold particles to tumors. Proc. Natl. Acad. Sci., 110(2), 465-470. doi: 10.1073/pnas.1219665110 Available at:
https://doi.org/10.1073/pnas.1219665110
Authors
Lan Yao, Jennifer Daniels, Anna Moshnikova, Sergey Kuznetsov, Aftab Ahmed, Donald M. Engelman, Yana
Reshetnyak, and Oleg A. Andreev
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/phys_facpubs/304
Corrections
APPLIED PHYSICAL SCIENCES, BIOPHYSICS AND COMPUTATIONAL
BIOLOGY
Correction for “Cancer radiotherapy based on femtosecond IR
laser-beam ﬁlamentation yielding ultra-high dose rates and zero
entrance dose,” by Ridthee Meesat, Hakim Belmouaddine, Jean-
François Allard, Catherine Tanguay-Renaud, Rosalie Lemay,
Tiberius Brastaviceanu, Luc Tremblay, Benoit Paquette, J. Richard
Wagner, Jean-Paul Jay-Gerin, Martin Lepage, Michael A. Huels,
and Daniel Houde, which appeared in issue 38, September 18,
2012, of Proc Natl Acad Sci USA (109:E2508–E2513; ﬁrst published
August 27, 2012; 10.1073/pnas.1116286109).
The authors note that they omitted a reference to an article by
Dumont et al. The complete reference appears below.
Also, on page E2512, right column, third full paragraph, lines
1–3 “pGEM-3Zf(-) plasmid DNA (3,197 bp, Promega) was ex-
tracted form Escherichia coli DH5α and puriﬁed with the QIA-
ﬁlter Plasmid Giga Kit (Qiagen)” should instead appear as
“pGEM-3Zf(-) plasmid DNA (3,197 bp, Promega) was prepared
in the laboratory of Dr. Darel Hunting. The plasmid was ampliﬁed
and extracted from Escherichia coli JM109 and puriﬁed with the
QIAﬁlter Plasmid Giga Kit (Qiagen) followed by removal of tris-
EDTA buffer using homemade Sephadex G50 (Pharmacia) col-
umns, according to the method published by Dumont et al. (56).”
Lastly, the following statement should be added to the
Acknowledgments: “The authors wish to thank Dr. Darel Hunting
for providing the plasmid DNA used in this work.”
www.pnas.org/cgi/doi/10.1073/pnas.1301033110
ECOLOGY
Correction for “A common rule for decision making in animal
collectives across species,” by Sara Arganda, Alfonso Pérez-
Escudero, and Gonzalo G. de Polavieja, which appeared in
issue 50, December 11, 2012, of Proc Natl Acad Sci USA
(109:20508–20513; ﬁrst published November 28, 2012; 10.1073/
pnas.1210664109).
The authors note that on page 20509, left column, ﬁrst full
paragraph, line 15, “α ¼ðlogðaÞ þ logð1=0:95− 1ÞÞ=logðsÞ” should
instead appear as “α ¼ðlogðaÞ− logð1=0:95− 1ÞÞ=logðsÞ”. This
typographical error does not affect the calculations or conclusions
of the article.
www.pnas.org/cgi/doi/10.1073/pnas.1222108110
APPLIED BIOLOGICAL SCIENCES
Correction for “pHLIP peptide targets nanogold particles to
tumors,” by Lan Yao, Jennifer Danniels, Anna Moshnikova,
Sergey Kuznetsov, Aftab Ahmed, Donald M. Engelman, Yana K.
Reshetnyak, and Oleg A. Andreev, which appeared in issue 2,
January 8, 2013, of Proc Natl Acad Sci USA (110:465–470; ﬁrst
published December 24, 2012; 10.1073/pnas.1219665110).
The authors note that the author name Jennifer Danniels
should instead appear as Jennifer Daniels. The corrected author
line appears below. The online version has been corrected.
Lan Yao, Jennifer Daniels, Anna Moshnikova,
Sergey Kuznetsov, Aftab Ahmed, Donald M. Engelman,
Yana K. Reshetnyak, and Oleg A. Andreev
www.pnas.org/cgi/doi/10.1073/pnas.1300604110
PHARMACOLOGY
Correction for “Local injection of dsRNA targeting calcitonin
receptor-like receptor (CLR) ameliorates Clostridium difﬁcile toxin
A-induced ileitis,” by Aditi Bhargava, Matthew S. Clifton, Pallavi
Mhsake, Min Liao, Charalabos Pothoulakis, Susan E. Leeman,
and Eileen F. Grady, which appeared in issue 2, January 8, 2013, of
Proc Natl Acad Sci USA (110:731–736; ﬁrst published December
24, 2012; 10.1073/pnas.1219733110).
The authors note that the author name Pallavi Mhsake should
instead appear as Pallavi Mhaske. The corrected author line
appears below. The online version has been corrected.
Aditi Bhargava, Matthew S. Clifton, Pallavi Mhaske,
Min Liao, Charalabos Pothoulakis, Susan E. Leeman,
and Eileen F. Grady
www.pnas.org/cgi/doi/10.1073/pnas.1301038110
56. Dumont A, Zheng Y, Hunting D, Sanche L (2010) Protection by organic ions against
DNA damage induced by low energy electrons. J Chem Phys 132(4):045102.
www.pnas.org PNAS | February 26, 2013 | vol. 110 | no. 9 | 3651
CO
RR
EC
TI
O
N
S
pHLIP peptide targets nanogold particles to tumors
Lan Yaoa,1,2, Jennifer Danielsa,2, Anna Moshnikovaa, Sergey Kuznetsova, Aftab Ahmedb, Donald M. Engelmanc,3,
Yana K. Reshetnyaka, and Oleg A. Andreeva,3
aPhysics Department, University of Rhode Island, Kingston, RI 02881; bDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University
of Rhode Island, Kingston, RI 02881; and cDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511
Contributed by Donald M. Engelman, November 12, 2012 (sent for review March 13, 2012)
Progress in nanomedicine depends on the development of nano-
materials and targeted delivery methods. In this work, we describe
a method for the preferential targeting of gold nanoparticles to
a tumor in a mouse model. The method is based on the use of the
pH Low Insertion Peptide (pHLIP), which targets various imaging
agents to acidic tumors. We compare tumor targeting by nonfunc-
tionalized nanogold particles with nanogold–pHLIP conjugates,
where nanogold is covalently attached to the N terminus of pHLIP.
Our most important ﬁnding is that both intratumoral and i.v. ad-
ministration demonstrated a signiﬁcant enhancement of tumor up-
take of gold nanoparticles conjugated with pHLIP. Statistically
signiﬁcant reduction of gold accumulation was observed in acidic
tumors and kidney when pH-insensitive K-pHLIP was used as a ve-
hicle, suggesting an important role of pH in the pHLIP-mediated
targeting of gold nanoparticles. The pHLIP technology can substan-
tially improve the delivery of gold nanoparticles to tumors by pro-
viding speciﬁcity of targeting, enhancing local concentration in
tumors, and distributing nanoparticles throughout the entire tu-
mor mass where they remain for an extended period (several
days), which is beneﬁcial for radiation oncology and imaging.
membranes | nanoparticle targeting | tumor acidity
Targeting of therapeutic nanoparticles could reduce sideeffects in treating cancer, as most antitumor drugs are toxic,
killing not only tumor cells but also causing serious damage to
healthy cells. One signiﬁcant difference between tumors and
normal tissues is that the former exhibit an acidic extracellular
environment (1). Acidosis is a hallmark of tumor development
both at very early and advanced stages (2, 3), as a consequence of
anaerobic metabolism (the Pasteur effect) (4), the activity of
carbonic anhydrases IX and XII (5), and the “aerobic glycolysis”
known as the Warburg effect (6). Thus, the targeting of most
solid tumors might be achieved by using pH-sensitive drugs and
delivery systems.
We have been developing a unique approach for targeting
acidic tissue, based on the family of pH (Low) Insertion Peptides
(pHLIPs). pHLIPs are water-soluble, moderately hydrophobic
polypeptides originally derived from the bacteriorhodopsin C
helix. A pHLIP is triggered by acidity to fold and insert across
a membrane to form a stable transmembrane alpha helix (7).
At neutral pH, pHLIP is in equilibrium between soluble and
membrane-bound unstructured forms, whereas in a low-pH en-
vironment, the protonation of negatively charged residues (Asp
or Glu) (8, 9) enhances peptide hydrophobicity, increasing the
afﬁnity of the peptide for the lipid bilayer and triggering peptide
folding and subsequent membrane insertion (8, 10). The Gibbs
free energy of pHLIP binding to a 1-Palmitoyl-2-Oleoyl-sn-
Glycero-3-Phosphocholine (POPC) from Avanti Polar Lipids
liposome surface at 37 °C is about –7 kcal/mol near neutral pH,
and the additional free energy of folding and insertion across
a lipid bilayer at low pH is nearly –2 kcal/mol (11). Thus, the
afﬁnity of the peptide for a membrane at low pH is several times
higher than at neutral pH, allowing pHLIP to distinguish and
mark acidic diseased tissue (8, 10, 12, 13). We have shown that
the N terminus of pHLIP stays outside of the bilayer, whereas
the C terminus inserts across the lipid bilayer at low pH (14, 15).
Small molecules (mostly imaging agents) covalently conjugated
with the N terminus of pHLIP can be delivered to tumors where
they are tethered to cell surfaces at low pH (12, 13, 16). As
a control for pH targeting in vivo we have used K-pHLIP, where
the Asp residues in the transmembrane part of a pHLIP are
replaced by Lys residues. K-pHLIPs lack pH-dependent in-
sertion into liposome phospholipid bilayers or cell membranes in
vitro or in vivo (12, 13, 16). K-pHLIP labeled with ﬂuorescent
dyes and PET and Single-Photon Emission Computed Tomogra-
phy (SPECT) agents show no targeting of tumors compared with
the WT-pHLIP (12, 13, 16, 17). pHLIP peptides conjugated with
optical and PET imaging probes are listed as pH targeting agents
in the Molecular Imaging and Contrast Agent Database, Na-
tional Center for Biotechnology Information. The results of
a study demonstrating tumor targeting by SPECT-pHLIP has
been published recently (17).
Davies et al. recently reported the pHLIP-mediated, pH-con-
trolled delivery of 13 nm water-soluble gold nanoparticles coated
with luminescent europium into human platelets in vitro (18). In
related work presented here, we show that pHLIP not only
induces the binding of 1.4 nm gold nanoparticles to cancer cells at
acidic pH in vitro but also that it stabilizes binding in tumors
established in mice. Gold is an inert and nontoxic material with
unique properties suitable for many applications such as cancer
diagnosis and treatment (19–21). For example, the irradiation of
gold atoms at their k-edge excitation energy (soft X-rays) will
generate Auger electrons or highly reactive species that may
produce a clinically achievable dose enhancement of as much as
10-fold, capable of local inactivation of biological molecules (22,
23). The targeted delivery of gold to diseased tissue that we
demonstrate here could lead to the successful application of gold
nanoparticles in the diagnosis and treatment of tumors.
Results
Biophysical Studies. Changes of tryptophan ﬂuorescence and CD
spectral signals can be used to monitor pHLIP binding to a
membrane lipid bilayer at neutral pH and insertion at lower pH
(7). We found that nanogold attached to pHLIP signiﬁcantly
quenches tryptophan ﬂuorescence, making it unreliable for use
in monitoring pHLIP insertion into a membrane (nevertheless,
a wavelength shift of the tryptophan ﬂuorescence maximum was
observed). Because gold nanoparticles are achiral in the UV
range (24) and do not interfere with the CD signals of a peptide,
we used the CD spectra of gold-pHLIP to study peptide–bilayer
interactions. Our data show that pHLIP attached to nanogold is
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predominantly unstructured at pH 8.0 in the absence or presence
of liposomes, whereas we observed helix formation at low pH in
the presence of POPC liposomes (Fig. 1). Thus, we conclude that
the attachment of gold nanoparticles to the N terminus of
pHLIP did not interfere with the ability of the peptide to form
a helical structure interacting with the membrane at low pH.
Based on our other studies, we interpret these data to indicate
that the pHLIP inserts into the membrane at low pH.
Nanogold Uptake by Cultured Cells. We compared the binding of
gold-pHLIP or gold nanoparticles to cultured cells at neutral and
low pHs. Nanoparticles (2 μM, 200 μL) were incubated with
HeLa–GFP cells at pH 7.4 or 6.5. After 1 h, cells were washed,
ﬁxed, and stained with silver enhancement solution, resulting in
the deposition of silver on gold nanoparticles to form microm-
eter-sized particles, which were visualized under a light micro-
scope (Fig. 2). The images on Fig. 2 were analyzed according to
Eq. 2 (Methods) to establish the ratios of gold (and silver) con-
centrations between the cells treated with gold-pHLIP or gold
nanoparticles and the untreated cells at pH 7.4 and 6.5. Cells
treated with gold-pHLIP nanoparticles at both pHs (Fig. 2 C and
G) showed higher uptake of gold (threefold at pH 7.4 and
6.4-fold at pH 6.5) compared with cells treated with unmodiﬁed
gold nanoparticles (Fig. 2 B and F). Cellular uptake of gold-
pHLIP nanoparticles at pH 6.5 (Fig. 2 G and H) was 1.6 times
higher than that at pH 7.4 (Fig. 2 C and D). These data dem-
onstrated the pH-dependent, pHLIP-mediated uptake of gold
nanoparticles by cells.
Animal Studies. When s.c. HeLa tumors reached 5–8 mm in di-
ameter, they were intratumorally or i.v. injected with gold
nanoparticles, gold-pHLIP, and gold-K-PHLIP conjugates. At
24 h after intratumoral administration of 15 μg gold or gold-pHLIP
nanoparticles, mice were euthanized, and the tumors and major
organs were harvested. The amount of gold in the tissues and
organs was established by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS) analysis (Fig. 3A and Table S1). These
results indicated that up to 8 μg (i.e., 54% i.d./g) of gold per gram
of tumor was delivered by pHLIP and remained in the tumor
after 24 h, compared to 0.7 μg/g (8% i.d./g) in the case of non-
functionalized gold nanoparticles. Accumulation of gold was also
observed in kidneys (about 2.1 μg/g). Because small particles
(1.4 nm) were used in this study, it is likely that clearance was
predominantly urinary, as has been observed with ﬂuorescent-,
PET-, and SPECT-labeled pHLIP constructs (13, 17). We have
previously observed that the pHLIP can accumulate in kidneys
due to the low pH in the tubules (16, 25).
I.V. administration was given as two consecutive injections
within 24 h. Split dosing was used to avoid high-concentration-
mediated aggregation. Each injection contained 150 μL of 20 μM
gold-pHLIP, gold-K-pHLIP, or nonfunctionalized gold particles
(i.e., 45 μg). Necropsies were performed 24 h after the last in-
jection. These data showed that 1.4 μg of gold per gram (1.5%
i.d./g) of tissue was delivered by pHLIP to the tumors (Fig. 3B
and Table S1). When pH-nonsensitive K-pHLIP was used as
a delivery vehicle, tumor targeting was reduced threefold (0.47
μg/g or 0.5%). The uptake of gold-K-pHLIP was also reduced
threefold in kidneys, and the distribution in other organs was
similar to gold-pHLIP.
To assess distribution of these gold nanoparticles within the
tissues, tumors, kidneys, and livers were collected and sectioned
4 h and 24 h after gold-pHLIP or gold nanoparticle administration.
Silver enhancement was used to visualize the gold nanoparticles
Fig. 1. CD spectra of gold-pHLIP in buffer pH 8.0 (state I) and in the pres-
ence of POPC liposomes at pH 8.0 (state II) and pH 4.0 (state III).
Fig. 2. Cellular uptake of gold-pHLIP and gold nanoparticles. Nanoparticles
(2 μM, 200 μL) were incubated with HeLa-GFP cells at pH 7.4 or 6.5. After 1 h,
cells were washed, ﬁxed, and stained with silver enhancement solution,
resulting in the deposition of silver on gold nanoparticles to form microm-
eter-sized particles, which were visualized under a light microscope The
images A–G and D–H were taken with 10× and 40× objectives, respectively.
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in tissue sections. The same conditions of silver enhancement
were used for all slides shown in Fig. 4. The amount of gold/silver
correlated with the darkness of the tissue sections. These data
show that gold distribution within the tumors, kidney, and liver
were higher and uniform at both time points for gold-pHLIP in-
jection than for unmodiﬁed gold administration.
The sections were further analyzed under a microscope with
10× (Fig. 5) and 100× (Fig. 6) objectives. The gold distribution in
tumors and livers (Fig. 5 D and L) was homogeneous, in contrast
to the distribution in kidneys (Fig. 5H), where the gold was mostly
accumulated in the cortex. Cellular localization was conﬁrmed
by staining of cell nuclei with DAPI (Fig. 6). The images of the
tumor sections demonstrated that pHLIP was distributed
throughout the entire tumor mass, penetrating to the cells in the
tumor interior and labeling the extracellular space and cellular
membrane (Fig. 6 A–C).
Discussion
Gold nanoparticles are of interest as potential diagnostic and
therapeutic agents in vivo, as they can be used as X-ray contrast
agents (26), radiation enhancers (27), and laser (28, 29) and
radiofrequency (30) thermotherapy enhancers. If tumors can be
loaded with gold, this would lead to a higher dose to the cancerous
tissue compared with the dose received by normal tissue during
a radiotherapy treatment. Calculations indicate that the dose en-
hancement can be signiﬁcant, as much as 200% or greater (27).
Gold nanoparticles are not toxic: the LD50 of this material is
∼3.2 g (Au) per kg of body weight–1 (26). Thus, the targeted de-
livery of gold nanoparticles could improve the treatment of cancers.
In general, one might suppose that speciﬁc delivery can be
accomplished by conjugating gold or any other nanoparticle to
antibodies or ligands that target proteins overexpressed on
cancer cell surfaces, and this approach has been actively explored
for many years for delivery of small molecules. However, several
recent studies have raised serious questions on the efﬁcacy of
targeting ligands on nanoparticle accumulation in tumor tissues,
showing that targeted nanoparticles did not accumulate more
than nontargeted controls, although increased cellular uptake
was observed in each case (31–33). In addition, histological
studies revealed that gold nanoparticles conjugated with anti-
bodies do not penetrate deeply into tumors, but mostly stain
peripheral tumor regions (34). The direct injection of μm-sized
gold particles does not lead to tumor targeting, as particles re-
main at the injection site and are not able to diffuse even within
a tumor, hindering tumor coverage (22).
In the present work, we report the promising ﬁnding that
pHLIP can enhance i.v. delivery of gold nanoparticles to tumors
by sixfold. On the other hand, nano-sized gold particles with no
conjugated pHLIP were washed out quickly from tumors and
other organs. Targeting with the pH-insensitive K-pHLIP (wherein
two Asp residues were replaced by Lys) resulted in statistically
signiﬁcant threefold reductions of gold accumulation. We in-
terpret these data as showing that the preferential distribution of
pHLIP-targeted gold is mediated by the acidosis present in
tumors and kidneys. The direct injection of gold-pHLIP into
tumors resulted in nearly uniform labeling of cancer cells with
gold nanoparticles throughout the entire tumor, revealing that
the pHLIP targeting allows migration within acidic regions to
target the entire mass. Direct injection resulted in accumulationFig. 3. ICP-MS analysis of the amount of gold in the excised tissues. Either
a single intratumoral injection of gold-pHLIP or gold nanoparticles (A; 20
μM, 50 μL) or two i.v. injections of gold-pHLIP, gold-K-pHLIP, and gold (B; 20
μM, 150 μL each) were given to mice bearing s.c. tumors. Organs were col-
lected at 24 h after the last injection. Organ uptakes of gold via intratumoral
and IV injections are shown in A and B, respectively. The amount of gold per
gram of tissue is given in Table S1. Mean ± SEM values are shown; *P <
0.0001 vs. respective value of tumor uptake of gold targeted by gold-pHLIP.
Fig. 4. Accumulation of gold-pHLIP (D, E, I, J, N, O) and gold nanoparticles
(B, C, G, H, L,M) in tumor (A, B, C, D, E), kidney (F, G, H, I, J) and liver (K, L,M,
N, O). Control tissues were taken from untreated mouse (A, F, K). The slices
indicated by an asterisk were not treated with silver enhancement solution.
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of 8.1 μg/g (54% i.d./g) in the tumor after 24 h. An N-fold in-
crease in diameter gives N3 increase in number of gold atoms per
particle, so with gold particles of 14 nm it might be possible to
increase the amount of gold 1,000-fold and to reach about 1% of
gold of tumor mass, which is the amount that would be needed
for a signiﬁcant enhancement of the radiation therapeutic effect.
Because the pHLIP-gold migrates to occupy the entire tumor, an
excellent therapy might result.
This work demonstrates that pHLIP can mediate targeted
delivery of nanoparticles to tumors and that direct injection
can result in distribution throughout the tumor mass. Further
improvements of nanoparticle coatings may be able to improve
bioavailability, enhance tumor targeting, and reduce accumula-
tion in nontarget organs. pHLIP technology can substantially
improve the delivery of gold nanoparticles to primary tumors
(and possibly metastatic lesions) by providing speciﬁcity of tar-
geting, enhancing local concentrations, and improving retention
in the tumor mass for an extended period (several days).
Methods
Peptide Conjugation with Gold Nanoparticles. The pHLIP (ACEQNPIYWAR-
YADWLFTTPLLLLDLALLVDADET) and K-pHLIP (ACEQNPIYWARYAKWLFTTP-
LLLLKLALLVDADET) peptides were prepared by Dr. James I. Elliott at the
W. M. Keck Foundation Biotechnology Resources Laboratory at Yale Uni-
versity. Monomaleimido Nanogold and nonfunctionalized particles (1.4 nm)
Fig. 5. Photomicrographs (10×) of tumor (A–D), kidney (E–H) and liver (I–L) sections non-enhanced (A, E, I, C, G, K) or enhanced (B, F, J, D, H, L) with silver
after injection of nanogold (A, B, E, F, I, J) or nanogold-pHLIP (C, D, G, H, K, L) particles.
Fig. 6. Distributions of gold-pHLIP enhanced by silver in tumor (A, B, C), kidney (D, E, F) and liver (G, H, I). Slices were visualized under an inverted optical
microscope with a 100× objective. The nuclei were stained with DAPI (blue color, B, E, H). Bright ﬁeld (A, D, G) and ﬂuorescent (B, E and H) images of the same
sections and their overlays (C, F, and I) of tumor, kidney, and liver slices are presented.
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were from Nanoprobes. A pHLIP peptide containing a single cysteine residue
near its N terminus was conjugated with the single maleimide group on each
nanogold particle. The progress of the coupling reaction was monitored by
reversed phase HPLC. The concentration of peptide and nanogold was de-
termined by absorbance at 280 nm (e = 13,940 M−1·cm−1) and 420 nm (e =
155,000 M−1·cm−1), respectively.
CD Measurements. CD measurements were carried out on a MOS-450 spec-
trometer (BioLogic) at 25 °C. Nonfunctionalized nanogold particles or
nanogold-pHLIP conjugates were preincubated with 200 mol excess of POPC
(1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine from Avanti Polar Lipids)
liposomes in 20 mM phosphate buffer, pH8.0. Liposomes with 50 nm di-
ameter were prepared by extrusion. To induce the folding/insertion of
peptide into the membrane lipid bilayer, HCl was added to lower the pH
value from 8 to 4. CD signals of gold nanoparticles were taken as base-
line signals and were subtracted from the corresponding signals of the
nanogold-pHLIP conjugates.
Cell Lines. HeLa cells (human cervix adenocarcinoma, ATCC) without and with
stable GFP expression were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% (vol/vol) FBS, 10 μg/mL of ciproﬂoxactin in
a humidiﬁed atmosphere of 5% (vol/vol) CO2 and 95% air (vol/vol) at 37 °C.
Some cells were adapted by serial passages to improve growth in low pH
medium (pH 6.5). The pH 6.5 medium was prepared by mixing 13.5 g of dry
DMEM with 0.2 g of sodium bicarbonate in 1 L of deionized water.
Experiments on Cultured Cells. HeLa-GFP cells grown in pH 6.5 or 7.4 media
were seeded in an eight-chamber slide (Lab-Tek, Thermo Scientiﬁc). At 80%
conﬂuency, cells were treated at pH 6.5 or 7.4 with 2 μM of nanogold or
nanogold-pHLIP in 200 μL of serum-free DMEM at 37 °C under 5% CO2. Cells
not treated with nanogold were used as negative controls. After incubation
for 1 h, the treatment solution was removed and cells were washed twice
with serum-free DMEM (pH 7.4) and once with sterile PBS (pH 7.4). Sub-
sequently, the cells were ﬁxed with cold methanol at –20 °C for 15 min and
then washed twice with sterile PBS (pH 7.4) and once with deionized water.
After air drying, the chamber walls were removed and the cell slides were
developed with freshly prepared HQ SILVER reagent (Nanoprobes). The re-
agent nucleates on the nanogold particles, resulting in the precipitation of
metallic silver and the formation of micrometer-sized particles with low
background. The developing time was varied until optimal conditions were
found (about 20 min). Subsequently, the cell slides were rinsed twice with
deionized water and viewed under a light microscope.
Estimation of Cellular Uptake of Gold/Silver Based on the Analysis of Cell
Images. After silver staining, the brightﬁeld images of cells were analyzed
with the ImageJ program. For cells treated with nanogold, the mean in-
tensities of the ﬁelds with cells (Ii) and without cells (I0,i, background) were
calculated. The concentration of gold/silver (ci) can be represented as a mean
intensity according to the Beer–Lambert law:
ci =
Ai
«d
=
1
«d
ln
I0;i
Ii
; [1]
ci
cnt
=
ln

I0;i
.
Ii
,
ln

I0;nt
.
Int

;
[2]
where Ai is the absorbance; e is the extinction coefﬁcient, and d is the
thickness of the sample. For cells not treated with nanogold, cnt, Int, and I0,nt
correspond to the concentration of gold/silver, measured as the mean in-
tensities of the ﬁelds with and without cells, respectively. We assume that
the extinction coefﬁcient and thickness are the same for all slides, so that
the ratio of concentrations can be calculated according to Eq. 2 by knowing
the mean intensities.
Tumor Targeting inMice.Athymic female nudemice ranging in age from 4 to 6
wk andweighing from 15 to 18 gwere obtained fromHarlan Laboratories; 38
mice were used in the study. Mouse tumors were established by s.c. injection
of HeLa cells (106 cells/0.1 mL/ﬂank) in the right ﬂank of each mouse. When
tumors reached 5–8 mm in diameter, intratumoral or tail vein injections of
nanogold samples were performed. For intratumoral injection, 50 μL of 20
μM nanogold or nanogold-pHLIP in sterile PBS (pH 7.4) was given at each of
three different spots in each tumor. For tail vein injection, two consecutive
injections of 150 μL of 20 μM nanogold-pHLIP or nonfunctionalized nano-
gold and nanogold-K-pHLIP as controls were given within 24 h. Animals
were euthanized at 4 or 24 h after the last injection. Necropsy was per-
formed immediately after euthanasia. Tumors and major organs were col-
lected for further histological analysis and study using ICP-MS. Noninjected
mice with similar-sized tumors were used as negative controls.
All animal studies were conducted according to the animal protocol AN07-
01-015 approved by the Institutional Animal Care and Use Committee,
University of Rhode Island, in compliance with the principles and procedures
outlined in the National Institutes of Health Guide for the Care and Use
of Animals.
Histological Analysis of Tumors and Organs. The excised tumors and organs
were ﬁxed in 4% formalin in PBS solution (pH 7.4) for 24 h at 4 °C. Tissues
were then rinsed with sterile PBS (pH 7.4), blotted dry, and placed in 30%
sucrose in PBS solution for at least 24 h at 4 °C. Samples were mounted in
HistoPrep frozen tissue embedding medium (Fisher Scientiﬁc) and frozen in
the quick freezer chamber of a cryostat (Vibratome UltraPro5000, GMI) at
−80 °C. Samples were frozen only one time, to minimize tissue damage.
When the temperature of mounted frozen samples was equilibrated with
the working chamber temperature (−12 °C), the tissue was sectioned at
a thickness of 10–20 μm. Sections were mounted on microscope slides coated
with poly-lysine, dried in air, and washed with deionized water. Sub-
sequently, silver enhancement of gold nanoparticles was carried out (de-
veloping time, 10 min). In some cases, further staining with DAPI was
performed to stain cell nuclei. The stained section was covered with a drop
of mounting medium (Permount, Fisher Scientiﬁc) and then a cover slide was
placed over the medium. The slides were examined with an inverted ﬂuo-
rescence microscope (IX71 Olympus).
ICP-MS Analysis. Mouse tissue samples were dissolved in aqua regia, freshly
prepared by mixing concentrated nitric and hydrochloric acids in a volume
ratio of 1:3. If necessary, sonication or heating was used to facilitate the
digestion of tissue samples. Then the concentrated sample solutions were
diluted to 10 mL to give 2% nitric acid and analyzed via ICP-MS (Thermo-
Scientiﬁc ×7 series) against calibration standards IMS 103 (UltraScientiﬁc).
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